Atrial fibrillation and chronic kidney disease in hypertension: A common and dangerous triad

Dimitris Tsiachris, Costas Tsioufis, Patrizio Mazzone, Niki Katsiki, Christodoulos Stefanadis

Research output: Contribution to journalArticle

Abstract

Hypertension (HTN) and chronic kidney disease (CKD) often coexist sharing common pathophysiological factors that both in combination and separately induce fibrotic changes in the heart provoking atrial fibrillation (AF). AF, per se, is associated with a 4- to 5-fold increased risk of stroke and a 2-fold increased risk of all-cause death. The co-existence of AF with HTN and renal dysfunction considerably increases morbidity and mortality. Management of AF in hypertensive patients with CKD is complex and multidisciplinary, since these patients have both a prothrombotic state and a coagulopathy with an increased tendency for bleeding. Novel oral anticoagulants such as dabigatran, rivaroxaban and apixaban offer better efficacy and safety especially in patients without optimal treatment with vitamin K antagonists.

Original languageEnglish
Pages (from-to)111-120
Number of pages10
JournalCurrent Vascular Pharmacology
Volume13
Issue number1
Publication statusPublished - 2015

Fingerprint

Chronic Renal Insufficiency
Atrial Fibrillation
Hypertension
Renal Hypertension
Vitamin K
Anticoagulants
Cause of Death
Stroke
Hemorrhage
Morbidity
Safety
Mortality
Therapeutics

Keywords

  • Anticoagulants
  • Atrial fibrillation
  • Chronic kidney disease
  • Hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Atrial fibrillation and chronic kidney disease in hypertension : A common and dangerous triad. / Tsiachris, Dimitris; Tsioufis, Costas; Mazzone, Patrizio; Katsiki, Niki; Stefanadis, Christodoulos.

In: Current Vascular Pharmacology, Vol. 13, No. 1, 2015, p. 111-120.

Research output: Contribution to journalArticle

Tsiachris, D, Tsioufis, C, Mazzone, P, Katsiki, N & Stefanadis, C 2015, 'Atrial fibrillation and chronic kidney disease in hypertension: A common and dangerous triad', Current Vascular Pharmacology, vol. 13, no. 1, pp. 111-120.
Tsiachris, Dimitris ; Tsioufis, Costas ; Mazzone, Patrizio ; Katsiki, Niki ; Stefanadis, Christodoulos. / Atrial fibrillation and chronic kidney disease in hypertension : A common and dangerous triad. In: Current Vascular Pharmacology. 2015 ; Vol. 13, No. 1. pp. 111-120.
@article{00c649115e8a4f63bbc0614106069dba,
title = "Atrial fibrillation and chronic kidney disease in hypertension: A common and dangerous triad",
abstract = "Hypertension (HTN) and chronic kidney disease (CKD) often coexist sharing common pathophysiological factors that both in combination and separately induce fibrotic changes in the heart provoking atrial fibrillation (AF). AF, per se, is associated with a 4- to 5-fold increased risk of stroke and a 2-fold increased risk of all-cause death. The co-existence of AF with HTN and renal dysfunction considerably increases morbidity and mortality. Management of AF in hypertensive patients with CKD is complex and multidisciplinary, since these patients have both a prothrombotic state and a coagulopathy with an increased tendency for bleeding. Novel oral anticoagulants such as dabigatran, rivaroxaban and apixaban offer better efficacy and safety especially in patients without optimal treatment with vitamin K antagonists.",
keywords = "Anticoagulants, Atrial fibrillation, Chronic kidney disease, Hypertension",
author = "Dimitris Tsiachris and Costas Tsioufis and Patrizio Mazzone and Niki Katsiki and Christodoulos Stefanadis",
year = "2015",
language = "English",
volume = "13",
pages = "111--120",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Atrial fibrillation and chronic kidney disease in hypertension

T2 - A common and dangerous triad

AU - Tsiachris, Dimitris

AU - Tsioufis, Costas

AU - Mazzone, Patrizio

AU - Katsiki, Niki

AU - Stefanadis, Christodoulos

PY - 2015

Y1 - 2015

N2 - Hypertension (HTN) and chronic kidney disease (CKD) often coexist sharing common pathophysiological factors that both in combination and separately induce fibrotic changes in the heart provoking atrial fibrillation (AF). AF, per se, is associated with a 4- to 5-fold increased risk of stroke and a 2-fold increased risk of all-cause death. The co-existence of AF with HTN and renal dysfunction considerably increases morbidity and mortality. Management of AF in hypertensive patients with CKD is complex and multidisciplinary, since these patients have both a prothrombotic state and a coagulopathy with an increased tendency for bleeding. Novel oral anticoagulants such as dabigatran, rivaroxaban and apixaban offer better efficacy and safety especially in patients without optimal treatment with vitamin K antagonists.

AB - Hypertension (HTN) and chronic kidney disease (CKD) often coexist sharing common pathophysiological factors that both in combination and separately induce fibrotic changes in the heart provoking atrial fibrillation (AF). AF, per se, is associated with a 4- to 5-fold increased risk of stroke and a 2-fold increased risk of all-cause death. The co-existence of AF with HTN and renal dysfunction considerably increases morbidity and mortality. Management of AF in hypertensive patients with CKD is complex and multidisciplinary, since these patients have both a prothrombotic state and a coagulopathy with an increased tendency for bleeding. Novel oral anticoagulants such as dabigatran, rivaroxaban and apixaban offer better efficacy and safety especially in patients without optimal treatment with vitamin K antagonists.

KW - Anticoagulants

KW - Atrial fibrillation

KW - Chronic kidney disease

KW - Hypertension

UR - http://www.scopus.com/inward/record.url?scp=84930976931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930976931&partnerID=8YFLogxK

M3 - Article

C2 - 24837057

AN - SCOPUS:84930976931

VL - 13

SP - 111

EP - 120

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 1

ER -